Board to review second-quarter and half-year results on November 4

Results View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹1571.70

prior close

₹1562.40

announcement price

After-mkt

timing

Nifty Midcap 150market+1.1%+0.1% vs market

Pharmaceuticals peers, median of 174sector+1.2%-0.0% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.4

15m

+0.9

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2+1.1+0.1+1.2-0.0

Next day

+3.6pendingpending+3.1+0.4

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma will hold a board meeting on November 4, 2026 to approve its standalone and consolidated unaudited results for the quarter and half year ended September 30, 2026. The board will also consider an interim dividend for 2026-27. Trading remains closed until November 6 and reopens November 7.

Likely market impact

The upcoming results and any interim dividend may move the stock. No financial figures, dividend amount, or operating details are provided yet.